15 jun: Fredagens aktier: Cyklisk fremgang inden afgørende græsk valg
18 jun: USA/aktier: Græsk valg sender futures højere
15-06-2012 23:53:00

Merck Loses Nasonex Patent Suit; Says Likely to Appeal

Relateret indhold

By Ben Fox Rubin

Drug maker Merck & Co. (MRK) said a U.S. district court ruled against it in a patent-infringement suit involving Apotex Inc.

In 2009, Merck filed the suit in New Jersey in an effort to block Apotex, a Canadian generic drug manufacturer, from selling a generic copy of Merck's blockbuster allergy drug Nasonex before U.S. patent protection expires.

Apotex had challenged the validity of the U.S. patent covering Nasonex. Merck said its patent for Nasonex is due to expire in 2018.

Bruce N. Kuhlik, Merck's general counsel, said his company was pleased the court ruled that its patent on Nasonex is valid, but was disappointed the court said the patent wasn't infringed by Apotex's product.

"Today's decision reflects just one step in the lengthy patent litigation process, and we plan to review all of our options, including a likely appeal of the decision," Mr. Kuhlik said.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

In April, Merck said its first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed Friday at $38.94 and were down 14 cents after hours. The stock is up 3.3% year-to-date.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 15, 2012 17:53 ET (21:53 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Norwegian har skrevet toårig overenskomst med kabinepersonalet

05-02-2016 15:55:23
Norwegians kabineselskaber, Norwegian Kabinforening (NK) og fagforeningen Parat har de seneste uger forhandlet om en ny overenskomst for de kabineansatte i Danm..

Genmab/Danske: Storudsalg af aktier bør ikke give panderynker

05-02-2016 12:17:09
På overfladen kunne det se mystisk ud, at ventureselskabet Johnson & Johnson Innovation har solgt en stor del sin beholdning af aktier i biotekselskabet Genmab...

Aktier/åbning: Genmab falder markant i de første handler

05-02-2016 09:29:22
Det amerikanske udslag af aktier i Genmab får kursen til at droppe fredag morgen med 7,6 pct. til 741,50 kr. Det er Johnson & Johnson Innovation, der har solgt ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Novo kan på ny komme i fokus
2
Aktier/PFA: Kombination af flere faktorer fører til dyk
3
Aktier/middag: Genmab og Vestas rykker dybest i panikmarked
4
Aktier/åbning: Genmab, Vestas og Novo trækker ned
5
USA/Danske Invest: Snakken om recession vil forstumme

Relaterede aktiekurser

Merck & Co., Inc 48,40 -2,0% Fald i aktiekurs
Merck AND CO Inc 43,80 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
8. februar 2016 17:51:37
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160208.2 - EUROWEB6 - 2016-02-08 17:51:37 - 2016-02-08 17:51:37 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x